MAP6-mediated microtubule stabilization as therapeutic target

Target: MAP6 Composite Score: 0.500 Price: $0.50 Citation Quality: 45% neurodegeneration Status: proposed
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
✓ All Quality Gates Passed
Quality Report Card click to collapse
C+
Composite: 0.500
Top 75% of 1402 hypotheses
T4 Speculative
Novel AI-generated, no external validation
Needs 1+ supporting citation to reach Provisional
C+ Mech. Plausibility 15% 0.55 Top 67%
C+ Evidence Strength 15% 0.50 Top 65%
C+ Novelty 12% 0.50 Top 91%
C+ Feasibility 12% 0.50 Top 62%
F Impact 12% 0.00 Top 50%
F Druggability 10% 0.00 Top 50%
F Safety Profile 8% 0.00 Top 50%
F Competition 6% 0.00 Top 50%
F Data Availability 5% 0.00 Top 50%
F Reproducibility 5% 0.00 Top 50%
Evidence
1 supporting | 0 opposing
Citation quality: 0%
Debates
1 session B+
Avg quality: 0.72
Convergence
0.00 F 4 related hypothesis share this target

Hypotheses from Same Analysis (2)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

MAP6-CRMPS cooperative phosphorylation by GSK3β
Score: 0.700 | Target: MAP6/CRMP2
Activity-dependent MAP6 scaffolding at synapses
Score: 0.600 | Target: MAP6

Description

Aberrant MAP6 function may contribute to tau-independent cytoskeletal defects in neurodegeneration, and stabilizing MAP6-microtubule interactions pharmacologically could compensate for Tau pathology

Prediction: Small molecules enhancing MAP6-microtubule binding will ameliorate cytoskeletal defects in tau knockout neurons and improve neuronal survival in amyloid toxicity models

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

flowchart TD
    A["MAPT/Tau Occupancy
Dynamic Microtubule Binding"] B["MAP6 Occupancy
Cold-Stable Domain Support"] C["Shared Microtubule Lattice
Domain Allocation Competition"] D["GSK3B/CRMP2 Cue Integration
Plasticity Signaling"] E["Axonal Remodeling Balance
Stable vs Labile Segments"] F["Transport and Branching
Adaptive Circuit Plasticity"] G["Tau-MAP6 Imbalance
Rigid or Unstable Cytoskeleton"] A --> C B --> C C --> D D --> E E --> F G -.->|"disrupts"| C style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7 style B fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7 style F fill:#1b5e20,stroke:#81c784,color:#81c784 style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a

3D Protein Structure (AlphaFold)

Open full viewer

AlphaFold predicted structure available for Q96JE9

View AlphaFold Structure

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.55 (15%) Evidence 0.50 (15%) Novelty 0.50 (12%) Feasibility 0.50 (12%) Impact 0.00 (12%) Druggability 0.00 (10%) Safety 0.00 (8%) Competition 0.00 (6%) Data Avail. 0.00 (5%) Reproducible 0.00 (5%) KG Connect 0.50 (8%) 0.500 composite
1 citations 0 with PMID Validation: 0% 1 supporting / 0 opposing
For (1)
No supporting evidence
No opposing evidence
(0) Against
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
1
MECH 1CLIN 0GENE 0EPID 0
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
Aberrant MAP6 function may contribute to tau-indep…SupportingMECH------
Legacy Card View — expandable citation cards

Supporting Evidence 1

Aberrant MAP6 function may contribute to tau-independent cytoskeletal defects in neurodegeneration, and stabil…
Aberrant MAP6 function may contribute to tau-independent cytoskeletal defects in neurodegeneration, and stabilizing MAP6-microtubule interactions pharmacologically could compensate for Tau pathology

Opposing Evidence 0

No evidence recorded
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.
Artifact Review | 4 rounds | 2026-04-25 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses

Theoretical Evaluation: MAP6 and CRMPs in Neuronal Function and Neurodegeneration

1. Key Scientific Contributions

1.1 Unification of MAP6's Pleiotropic Functions Under a Single Conceptual Framework


This review synthesizes two decades of work demonstrating that MAP6 (STOP) is far more than a microtubule stabilizer. The authors establish MAP6 as a signaling scaffold that coordinates microtubule dynamics, actin cytoskeleton remodeling, and receptor trafficking. This reframing is significant because it positions MAP6 as a potential integrator of cytoskeletal responses to neuronal ac

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns

Critical Evaluation: MAP6 and CRMPs Review Article

1. Key Methodological Weaknesses

1.1 Literature Synthesis Lacks Systematic Rigor


This is a narrative review, not a systematic review. The authors present their interpretation of "extensive data obtained over 20 years" without transparent inclusion/exclusion criteria for studies. This introduces selection bias—the review naturally emphasizes work from the authors' own laboratory (Grenoble Institut Neurosciences) while potentially underrepresenting conflicting findings. A cursory PubMed search reveals that several key authors appe

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation

Expert Assessment: MAP6 and CRMPs Review Article (PMID: 34025352)

1. Novelty Rating: 6/10

This review provides moderate conceptual novelty within the broader MAP/c cytoskeleton field.

Strengths:

  • First comprehensive synthesis linking MAP6 to such a diverse array of neuronal functions
  • The MAP6-CRMPS convergence framework is genuinely informative, as these protein families have been studied largely in parallel
  • The "beyond stabilization" framing articulates an important shift in thinking about MAPs generally
Limitations:
  • As a narrative review, novelty is constrained by

Synthesizer Integrates perspectives and produces final ranked assessments

{"summary":"This 2021 review from the Grenoble research group synthesizes two decades of research on MAP6 (STOP), repositioning it from a simple microtubule stabilizer to a multifunctional signaling scaffold that coordinates cytoskeletal dynamics, actin remodeling, and receptor trafficking. The authors articulate a convergence framework linking MAP6 to the CRMP family (collapsin response mediator proteins), highlighting shared roles in semaphorin signaling, axon guidance, and GSK3β-mediated phosphorylation. The review extends MAP6 function beyond microtubule binding to encompass synaptic plast

Price History

0.490.500.51 0.52 0.48 2026-04-252026-04-252026-04-25 Market PriceScoreevidencedebate 1 events
7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0000
Events (7d)
1

Clinical Trials (0) Relevance: 60%

No clinical trials data available

📚 Cited Papers (0)

No linked papers yet

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

📓 Linked Notebooks (0)

No notebooks linked to this analysis yet. Notebooks are generated when Forge tools run analyses.

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas
→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Moderate Efficiency Resource Efficiency Score
0.50
31.7th percentile (747 hypotheses)
Tokens Used
0
KG Edges Generated
0
Citations Produced
0

Cost Ratios

Cost per KG Edge
0.00 tokens
Lower is better (baseline: 2000)
Cost per Citation
0.00 tokens
Lower is better (baseline: 1000)
Cost per Score Point
0.00 tokens
Tokens / composite_score

Score Impact

Efficiency Boost to Composite
+0.050
10% weight of efficiency score
Adjusted Composite
0.550

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

Related Hypotheses

Tau/MAP6 antagonism in neurodegeneration progression
Score: 0.650 | neurodegeneration
Domain boundary cross-talk hypothesis
Score: 0.600 | neurodegeneration
Activity-dependent MAP6 scaffolding at synapses
Score: 0.600 | neurodegeneration
Tau-Independent Microtubule Stabilization via MAP6 Enhancement
Score: 0.567 | neurodegeneration

Estimated Development

Estimated Cost
$0
Timeline
0 months

🧪 Falsifiable Predictions

No explicit predictions recorded yet. Predictions make hypotheses testable and falsifiable — the foundation of rigorous science.

Knowledge Subgraph (0 edges)

No knowledge graph edges recorded

Predicted Protein Structure

🔮 MAP6 — AlphaFold Prediction Q96JE9 Click to expand 3D viewer

AI-predicted structure from AlphaFold | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)